Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anaptysbio (ANAB) EBT (2016 - 2025)

Anaptysbio filings provide 10 years of EBT readings, the most recent being $62.8 million for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 386.21% year-over-year to $62.8 million, compared with a TTM value of -$84.7 million through Sep 2025, down 3985.48%, and an annual FY2024 reading of -$145.4 million, down 337962.79% over the prior year.
  • EBT hit $62.8 million in Q4 2025 for Anaptysbio, up from $15.1 million in the prior quarter.
  • The five-year high for EBT was $121.4 million in Q4 2023, with the low at -$46.7 million in Q2 2024.
  • Median EBT over the past 5 years was -$29.2 million (2021), compared with a mean of -$15.3 million.
  • The sharpest move saw EBT crashed 6121.91% in 2022, then soared 648.32% in 2023.
  • Year by year, EBT stood at -$31.1 million in 2021, then grew by 28.8% to -$22.1 million in 2022, then surged by 648.32% to $121.4 million in 2023, then plummeted by 118.07% to -$21.9 million in 2024, then soared by 386.21% to $62.8 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $62.8 million, $15.1 million, and -$38.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.